Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

3.2K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.2K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

797
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
797
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

681
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
681
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

3.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

641
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
641
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cat exposure and asthma outcomes in a cohort of children with asthma and allergy.

Frontiers in allergy·2026
Same author

Comparison of airway mucin 5AC and 5B expression in preterm-born adults and asthma.

ERJ open research·2026
Same author

Siglec expression in sentinel lymph nodes in patients with oral squamous cell carcinoma.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2026
Same author

Corrigendum to "Redox-dependent suppression of ATF3 impairs steroid sensitivity in asthma through MKP-1/p38 MAPK signaling" [Free Radic. Biol. Med. 243 (2026) 1-15].

Free radical biology & medicine·2026
Same author

Dog exposure and subsequent asthma outcomes in children with asthma and allergy.

The journal of allergy and clinical immunology. Global·2026
Same author

T Cell O-GlcNAcylation Increases in Patients With Allergic Rhinitis After the Natural Pollen Season.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026

Related Experiment Video

Updated: Oct 3, 2025

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.8K

IL-26 in asthma and COPD.

Eduardo I Cardenas1, Karlhans Fru Che1, Jon R Konradsen2,3,4

  • 1Division of Lung and Airway Research, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.

Expert Review of Respiratory Medicine
|February 21, 2022
PubMed
Summary
This summary is machine-generated.

Interleukin-26 (IL-26) is a potential diagnostic and therapeutic target for uncontrolled asthma and chronic obstructive pulmonary disease (COPD). Further research may confirm its role in personalized medicine for these airway diseases.

Keywords:
AsthmaCOPDIL-26Th17neutrophils

More Related Videos

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

2.1K
An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

7.5K

Related Experiment Videos

Last Updated: Oct 3, 2025

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.8K
Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

2.1K
An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

7.5K

Area of Science:

  • Immunology
  • Respiratory Medicine

Background:

  • Uncontrolled asthma and COPD require new diagnostic and therapeutic targets due to innate immune response alterations.
  • Interleukin-26 (IL-26), an IL-10-related cytokine, is highly expressed in human airways.
  • Altered IL-26 expression correlates with reduced lung function and neutrophilic inflammation in asthma and COPD patients.

Purpose of the Study:

  • To review the role of IL-26 in the pathophysiology of asthma and COPD.
  • To explore IL-26 as a potential biomarker and therapeutic target for airway diseases.

Main Methods:

  • A literature search was conducted on PubMed for studies on IL-26 immunology and clinical research in asthma and COPD (2000-2021).
  • The review outlines IL-26 sources, its effects on immune and structural cells, and its potential involvement in disease pathogenesis.

Main Results:

  • IL-26 is abundantly expressed in human airways.
  • Changes in IL-26 levels are associated with disease severity markers in asthma and COPD.
  • IL-26 influences key immune and structural cells in the airways.

Conclusions:

  • IL-26 presents a promising target for diagnosing and therapeutically modulating the innate immune response in asthma and COPD.
  • Clinical utility of IL-26 in personalized medicine is anticipated within the next five years.